GlobeNewswire: Lifecore Biomedical, Inc. Contains the last 10 of 182 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T11:56:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/16/2830931/0/en/Lifecore-Biomedical-Inc-Announces-Receipt-of-Nasdaq-Notice-of-Delisting-and-Intention-to-Appeal.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal2024-02-16T21:05:00Z<![CDATA[Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities]]>https://www.globenewswire.com/news-release/2024/01/12/2808820/0/en/Lifecore-Biomedical-Inc-Receives-Notice-from-Nasdaq-Regarding-Delayed-Quarterly-Report.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report2024-01-12T21:43:40Z<![CDATA[CHASKA, Minn., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on January 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company failed to timely file its Interim Report on Form 10-Q for the period ended November 29, 2023 (the “Q2 Form 10-Q”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the period ended May 28, 2023 (the “Form 10-K”) and its Quarterly Report on Form 10-Q for the fiscal quarter ended August 27, 2023 (the “Q1 Form 10-Q” and, together with the Form 10-K and the Q2 Form 10-Q, the “Filings”) with the Securities and Exchange Commission.]]>https://www.globenewswire.com/news-release/2024/01/05/2804602/0/en/Lifecore-Biomedical-Expands-Relationship-with-Existing-Long-Term-Customer-Through-a-Series-of-Commercial-Arrangements.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements2024-01-05T13:00:00Z<![CDATA[Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements]]>https://www.globenewswire.com/news-release/2023/12/13/2795460/0/en/Lifecore-Biomedical-Provides-Business-Update.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical Provides Business Update2023-12-13T12:30:00Z<![CDATA[CHASKA, Minn., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provided a business update.]]>https://www.globenewswire.com/news-release/2023/11/20/2783596/0/en/Company-Reaches-Favorable-Resolution-Regarding-Previously-Disclosed-Investigation-of-Formerly-Held-Subsidiary-Yucatan-Foods.html?f=22&fvtc=4&fvtv=17570Company Reaches Favorable Resolution Regarding Previously-Disclosed Investigation of Formerly-Held Subsidiary Yucatan Foods2023-11-20T21:05:00Z<![CDATA[U.S. Department of Justice Declines Prosecution U.S. Department of Justice Declines Prosecution]]>https://www.globenewswire.com/news-release/2023/10/18/2762736/0/en/Lifecore-Biomedical-Inc-Receives-Notice-from-Nasdaq-Regarding-Delayed-Annual-Report.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report2023-10-18T20:05:00Z<![CDATA[CHASKA, Minn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on October 12, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company failed to timely file its Interim Report on Form 10-Q for the period ended August 27, 2023 (the “Form 10-Q”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the period ended May 28, 2023 (the “Form 10-K” and, together with the Form 10-Q, the “Filings”) with the Securities and Exchange Commission.]]>https://www.globenewswire.com/news-release/2023/10/10/2757906/0/en/Lifecore-Biomedical-Provides-Update-for-Development-Portfolio-and-Timing-of-Delayed-Filings.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical Provides Update for Development Portfolio and Timing of Delayed Filings2023-10-10T20:05:00Z<![CDATA[CHASKA, Minn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provided an update on its delayed filings. The Company anticipates reporting its Fiscal 2024 First Quarter results in late October or early November, pending completion of its annual audit, and will make a formal announcement via press release once the date is established.]]>https://www.globenewswire.com/news-release/2023/08/31/2735143/0/en/Lifecore-Biomedical-Reports-Fourth-Quarter-and-Full-Fiscal-Year-2023-Results.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results2023-08-31T11:30:00Z<![CDATA[CHASKA, Minn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (Nasdaq: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 fourth quarter and full year ended May 28, 2023.]]>https://www.globenewswire.com/news-release/2023/08/22/2729997/0/en/Lifecore-Biomedical-Sets-Fourth-Quarter-2023-Earnings-Conference-Call-for-August-31-2023-at-7-30-a-m-CT.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CT2023-08-22T20:06:15Z<![CDATA[CHASKA, Minn., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a conference call to discuss fiscal 2023 fourth quarter financial results. The live webcast can be accessed via Lifecore’s website on the Investor Events & Presentations page. The webcast will be available for 30 days.]]>https://www.globenewswire.com/news-release/2023/08/22/2729995/0/en/Lifecore-Biomedical-Inc-Receives-Notice-from-Nasdaq-Regarding-Delayed-Annual-Report.html?f=22&fvtc=4&fvtv=17570Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report2023-08-22T20:05:06Z<![CDATA[CHASKA, Minn., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on August 17, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company failed to timely file its Annual Report on Form 10-K for the period ended May 28, 2023 (the “Form 10-K”) with the Securities and Exchange Commission.]]>